Image Credit: Canva
We've all been there, you use the toilet, try to stand up, and suddenly your legs go numb. That odd pins-and-needles feeling can be surprising and uncomfortable. Though it might feel like a small inconvenience, it does have a scientific explanation. The numbness, also called transient paresthesia, happens when pressure blocks blood flow or presses on nerves in your lower extremities. It is normally harmless, but frequent occurrences can be signs of underlying health issues or poor toilet habits that must be addressed.
That weird numbness you experience after going to the bathroom is typically just a temporary annoyance, most often due to bad posture, straining, or sitting for an extended period. But if the numbness continues or gets worse, it is important to get medical guidance to make sure there are no underlying health issues. We discovered the top three reasons that could be responsible for this tingling and how can you avoid it? Let's dissect.
Struggling to push during a bowel movement can put excessive pressure on your abdomen and spine. This increased pressure can shift spinal discs, pressing against nerves that extend into your legs and feet. The result? A temporary loss of sensation, tingling, or weakness in your lower limbs.
Straining usually results from constipation, which in turn can be caused by a low-fiber diet, dehydration, or inactivity. If you notice that you're straining frequently, perhaps it's time to change your eating and drinking habits to help move your bowels more easily.
The way you sit on the toilet can also be a cause of that numbness in your legs. Most people are prone to hunching over when they are using their phones, reading, or just focusing too intensely. But this position can compress nerves and blood vessels in your pelvis, causing tingling or numbness.
When you sit slumped forward, you cut off blood supply to the lower half of your body, compressing nerves that travel from your pelvis to your toes. That's why the numbness will often radiate past your thighs and into your toes.
The more time you spend sitting on the toilet, the higher your chance of getting numb legs. Protracted sitting continually puts pressure on the nerves within your lower limbs, slowing blood flow and leaving you with the familiar pins-and-needles feeling.
If you habitually stay on the toilet for a long time, either from digestive problems or distractions such as browsing your phone, you may find that there is more numbness over the course of time. If constipation is leaving you on the toilet longer than normal, diet changes can calm your system.
Although periodic tingling is not a health issue, recurring numbness is a problem that needs to be addressed. Below are some professional-recommended ways of preventing it:
Being seated with your knees higher than your hips can make all the difference. Sitting this way enables your colon to unwind, facilitating smooth bowel movements while minimizing pressure on the lower parts of your body.
Don't slouch, as this squishes nerves and blood vessels, making numbness more likely. If necessary, lean your back against the toilet tank or wall to keep your posture good.
Specialists recommend five to ten minutes of toilet time per visit. If you are straining, stand up, walk around, and try later. Forcing the bowel movement can cause more damage than benefit, putting greater pressure on your spine and worsening numbness.
If constipation is a chronic problem, being hydrated and consuming fiber foods such as fruits, vegetables, and whole grains can get your digestive system back in working order.
Raising your feet using a toilet stool may position your body for a more natural and strain-free bowel movement. A squatting position keeps the rectal canal open, minimizing the need to push and reducing the risk of leg numbness.
Hard toilet seats can restrict circulation in your lower body, increasing the risk of numbness. A cushioned or padded toilet seat can provide better support, improving blood flow to the legs and feet while reducing pressure on the pelvis.
While it's normal to have some numbness in your legs from time to time when sitting on the toilet, ongoing tingling or numbness in your lower extremities may be a symptom of an underlying medical condition. If you find yourself experiencing:
It's best to see a healthcare expert to exclude conditions such as nerve compression, circulatory disorder, or spinal condition.
Credit: iStock
Beyond weight loss and diabetes control, GLP-1 drugs may offer mental health benefits by reducing the need for psychiatric hospital care among people with schizophrenia and type 2 diabetes (T2D), according to a new study published in The Lancet Psychiatry.
The findings showed that treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) was associated with lower risks of psychiatric hospitalization and emergency department visits among people with both conditions.
Also read: Exclusive: GLP-1 Drugs Are The ‘New Statins’, Says University Hospital Birmingham Professor
Researchers from Deakin University and the University of Queensland in Australia analyzed US health records of more than 70,000 adults with schizophrenia and T2D who received treatment between January 2018 and October 2026.
The researchers found that people taking GLP-1 drugs were:
GLP-1 use was also associated with fewer psychiatric emergency department visits. Compared with the same groups, users were:
Further, when the researchers analyzed individual drugs, the association was observed with semaglutide, liraglutide, and tirzepatide, but not dulaglutide.
Read More: Ozempic Baby: Can GLP-1 Drugs Help Women With PMOS Conceive?
The researchers cautioned that the observational study cannot establish that GLP-1 drugs directly reduce the need for acute psychiatric care.
They said the medications should not be considered primary psychiatric treatments or prescribed solely to reduce psychiatric hospitalizations and emergency visits.
Instead, the findings point to a potential additional benefit when GLP-1 drugs are prescribed for appropriate metabolic indications as part of integrated cardiometabolic and mental health care.
“The findings suggest that lower psychiatric acute-care use could be a favourable secondary benefit when GLP-1-based therapies are clinically indicated for metabolic management,” the researchers said.
They added that randomized clinical trials and mechanistic studies are needed to determine whether the drugs have a direct effect on psychiatric outcomes. Further research should also investigate their potential benefits in people with schizophrenia who do not have T2D.
Schizophrenia is a serious psychiatric disorder associated with disability, other health conditions, and premature mortality. Cardiometabolic diseases, including T2D, contribute substantially to this burden.
Studies suggest that diabetes may be up to five times more common among people with schizophrenia than among those without the condition. Approximately one in five people with schizophrenia may also have diabetes.
Several factors may contribute to this increased risk, including:
GLP-1 receptor agonists are an established class of medications used to manage T2D and, in some cases, obesity. Their potential role in people with schizophrenia is of growing interest because of the high burden of metabolic disease in this population.
However, whether these medications directly improve psychiatric outcomes remains uncertain.
The latest findings suggest that GLP-1 treatment may be associated with reduced use of acute psychiatric care among people with schizophrenia and T2D. Further clinical trials are needed before any direct mental health benefit can be established.
Credit: iStock
Originally developed to treat type 2 diabetes and obesity, GLP-1 receptor agonists have shown benefits beyond blood sugar control and weight loss, including for cardiovascular and kidney health.
Some women, particularly those with polyendocrine metabolic ovarian syndrome (PMOS), formerly known
as PCOS, have reported conceiving after taking these medications.
Although GLP-1 drugs can support weight loss and improve metabolic health, evidence that they directly improve fertility remains limited.
For 30-year-old Ashlee Amborn, pregnancy was challenging. According to ABC News, she had PMOS, one functioning fallopian tube and half a uterus, which complicated her chances of conceiving naturally.
After years of fertility treatments, she conceived her first two children. Four months after her second child's birth, she became pregnant again.
Amborn said a GLP-1 drug prescribed to manage her PMOS symptoms, including inflammation and hormonal imbalances, helped her conceive. She became pregnant after taking the medication for a month.
"It was kind of these mixed emotions of, 'Holy cow, I'm pregnant,'" Amborn said. "I did this on my own without fertility treatment. All it took was a GLP-1."
Also read: Sorority Rush Sees Ozempic Trend: What Young Women Should Know Before Using GLP-1 Drugs
A recent review published in the Journal of the Brazilian Reproduction Association (JBRA) Assisted Reproduction suggests a possible association between GLP-1 use and improved fertility outcomes in women with obesity and PMOS, particularly those also taking metformin, a medication used to manage blood sugar.
Weight loss and improved insulin sensitivity may support ovulation and reduce ovarian dysfunction. However, more research is needed to establish whether these medications improve pregnancy or live-birth rates.
Dr. Jacinta Anyaoku, a physician at Maven Clinic specializing in obesity and women's health in midlife, told ABC News that research has not established a direct link between GLP-1 use and ovulation rates, although she has observed potential benefits among her patients.
"When you lose weight, your inflammation goes down," Anyaoku said. "It actually can help with improving your rate of ovulation. Your egg quality could potentially improve if you have reduced inflammation, and so these are all potential effects that come with GLP-1 use."
Sharrón L. Manuel, a board-certified OB/GYN and reproductive endocrinology specialist at HRC Fertility, attributes the reported "Ozempic Baby Boom" largely to weight loss and improved metabolic health, which may help restore ovulation.
Excess body weight can disrupt the hypothalamic-pituitary-ovarian (HPO) axis, contribute to insulin resistance and affect egg and uterine lining quality.
Manuel also points to preliminary research suggesting GLP-1 drugs may influence reproductive function through hormonal regulation, reduced inflammation and improved insulin sensitivity. However, preclinical findings involving ovarian function and endometrial receptivity require further investigation in humans.
Read More: GLP-1 Drugs Ozempic, Zepbound Use Rises 24-Fold Among American Women After Childbirth
GLP-1 drugs should not be used during pregnancy. Women planning to conceive should consult their healthcare professional about stopping treatment. For semaglutide, prescribing guidance recommends discontinuation at least two months before a planned pregnancy.
Women should also seek medical advice about using these medications while breastfeeding.
The American College of Obstetricians and Gynecologists advises against weight-loss medications during pregnancy. Women considering GLP-1 treatment should discuss the risks, benefits and timing with their healthcare professional, particularly if they plan to conceive.
Tirzepatide, sold under the brand names Mounjaro and Zepbound, can affect oral contraceptive absorption. Its prescribing information recommends switching to a non-oral contraceptive method or adding a barrier method for four weeks after starting treatment and for four weeks after each dose increase.
Credit: iStock
Parkinson’s disease (PD) symptoms differ between women and men, a new study has found, with potential implications for treatment.
Presented at the 2026 International Congress of Parkinson’s Disease and Movement Disorders in Seoul, the study found that women experienced more severe motor complications and depression. Men, however, had greater cognitive impairment.
“Sex differences in movement disorders remain understudied and undervalued despite having an important impact on clinical outcomes in both real-life and clinical trial settings,” said Dr. Marina Picillo, assistant professor of neurology at AOU San Giovanni di Dio e Ruggi d’Aragona.
Researchers retrospectively analyzed 10 years of clinical data from more than 10,000 Parkinson’s patients examined at a movement disorders clinic in Germany.
The findings showed that women had a greater burden of motor complications and depression. Men were more likely to experience cognitive impairment, REM sleep behavior disorder (RBD) and loss of smell.
“By analyzing data for more than 10,000 PD patients, this study confirmed that depression is more common in women, while RBD, worse cognition, and poorer olfaction are more prevalent in men,” Picillo said. “With good representation of women (40%), it also confirmed a greater female burden of motor complications.”
The findings highlight the need to account for sex differences in Parkinson’s disease management and clinical trial design, particularly given the historical underrepresentation of women in neurological research. However, the factors underlying these differences remain unclear.
Picillo stressed that considering sex differences when tailoring treatment and designing clinical trials could be an important first step toward precision medicine in Parkinson’s disease.
“This would be the very first, basic step for boosting precision medicine in PD,” she said.
Parkinson’s disease is a progressive neurodegenerative disorder caused by the loss of dopamine-producing nerve cells in the brain.
Common symptoms include tremors, muscle stiffness, slowed movement and impaired balance. As the disease progresses, patients may have difficulty walking, speaking and performing everyday tasks.
The condition can also cause cognitive impairment, depression, anxiety, sleep disturbances, pain and swallowing difficulties, affecting patients’ independence and quality of life. Although it primarily affects older adults, younger people can also develop Parkinson’s disease.
Parkinson’s disease affected an estimated 11.9 million people worldwide in 2021. The number is projected to reach 25.2 million by 2050, a 112% increase.
There is currently no established way to prevent Parkinson’s disease. However, research suggests that certain lifestyle and environmental factors may influence disease risk.
© $2026 Times Horizon Private Limited